Study of Atropine Therapeutic Effect on Myopic Progression

Inclusion Criteria: * Aged 5 to 12 years at the time of consent * Refractive error of SE at least -1.0 D and no greater than -8.0 D in both eyes as measured by cycloplegic autorefraction at visit 1 and visit 2. * Confirmed myopia progression of 0.5D or more within past 1year * Astigmatism of 2.5D or less in both eyes * Distance Best Corrective Visual Acuity to logMAR 0.2 or better in both eyes at visit1. * Normal IOP under 21mmHg in both eyes. * Anisometropia of SE less than 2.0D as measured by cycloplegic autorefraction at visit 1. * Written informed consent willingly obtained by both subject and his/her parents Exclusion Criteria: * Hypersensitivity to atropine or other cycloplegic agent. * History of the surgery of refractive correction * Having ocular disease affect to visual function or refractive error: history of glaucoma, macula r degeneration, diabetic eye disease, uveitis, etc, or presence of conjunctivitis at screening visit. * Having systemic diseases that affect to vision loss * Having risk of IOP elevation such as narrow angle, Shallow Anterior Chambers, etc * Presence of binocular function disorder or stereopsis disorder * Amblyopia or manifest strabismus * History of premature birth(less than 37weeks) or low birth weight(less than 2,500g) * Previous or current use of atropine or Ortho-K lens for myopia * Down syndrome, spastic paralysis, brain damage, spastic palsy, bladder * Presence of neurological diseases like epilepsy, etc. which could expect difficulties in compliant to the ocular examinations. * Presence of clinically significant cardiac and respiratory diseases * Participation in any other clinical study of an investigational product within 3-month prior to current IP administration. * Based on the investigator's discretion, subject who is not proper to participate in the trial.